pharma.markets

pharma.markets

  • HOME
  • Imprint

novartis

Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

04/02/2023 MaP 0

Overall, at Week 52, more than 60% of patients were free of flares1. Additionally, more than 50% experienced a meaningful reduction in pain, which has […]

Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

08/12/2022 MaP 0

Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary […]

Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer

06/12/2022 MaP 0

Ad hoc announcement pursuant to Art. 53 LR Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a […]

Novartis maintains growth momentum and confirms FY’22 Group guidance

25/10/2022 MaP 0

Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven […]

novartis

Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study

24/10/2022 MaP 0

Ad hoc announcement pursuant to Art. 53 LR Phase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal […]

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

06/06/2022 MaP 0

Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

12/12/2021 MaP 0

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of […]

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

12/12/2021 MaP 0

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation […]

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

09/12/2021 MaP 0

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall […]

Roche completed the repurchase of Roche shares from Novartis

06/12/2021 MaP 0

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November […]

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

19/11/2020 MaP 0

• Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other […]

Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

26/06/2020 MaP 0

• If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first […]

Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile

26/06/2020 MaP 0

• EMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis • CHMP opinion based on two Phase […]

Novartis Resolves Legacy FCPA Investigations

25/06/2020 MaP 0

Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act […]

Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

20/06/2020 MaP 0

• FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of […]

Posts navigation

1 2 »

Translation

Search

Categories

  • Age.related Degeneration
  • Alzheimer
  • Animal health
  • Asthma
  • Bioscience
  • Cancer
  • Conferences
  • Cosmetics
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Food
  • HHS
  • Humanitarian Aid
  • Imprint
  • Influenza
  • Innovation
  • Mental Health
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • Spain
  • Sports
  • Therapy
  • Trade Fair
  • UN
  • Vaccines
  • Valencia Comunidad
  • WHO

Reports

  • BioNTech Announces New ADS Repurchase Program
  • Merck Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry Education
  • Bayer expands global clinical program for darolutamide in prostate cancer
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections

Archive

  • March 2023 (17)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • BioNTech Announces New ADS Repurchase Program

    28/03/2023 0
  • Merck Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry Education

    27/03/2023 0
  • Bayer expands global clinical program for darolutamide in prostate cancer

    23/03/2023 0
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

    21/03/2023 0
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections

    20/03/2023 0
Archives
  • March 2023 (17)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid bayer biontech cancer commission companies coronavirus covid-19 covid19 economy elpais.com emergency eu europe european fda food global guarantee health hygiene investment links medical merck novartis pandemic pfizer production recommendations region response roche safety scheme sector spain state statistics support test vaccine who

Copyright © 2023 | WordPress Theme by MH Themes

Cookie Consent with Real Cookie Banner